A dodecapeptide EDIKPKTSLAFR ligand targeting CEN-1 human nasopharyngeal carcinoma (NPC) was identified by in vivo phage display. Two tridecapeptides and their derivatives, named YR13 (YEDIKPKTSLAFR), EY13 (EDIKPKTSLAFRY), EY13-NH 2 (EDIKPKTSLAFRY-NH 2 ) and Fmoc-YR13 (Fmoc-YEDIKPKTSLAFR), were synthesized and radiolabeled with 131 I. The stability in vitro, biodistribution and tissue distribution of selected phage particles in mice bearing NPC tumor were determined, and plasma metabolites analysis of radiolabeled peptides was carried out. Although Fmoc and NH 2 groups could protect the peptide from deiodination, only Fmoc group inhibited the binding of Fmoc-YR13 to NPC tumors. The compound EY13-NH 2 , the C-terminal amide of peptide EY13, had the greatest serum stability, the least deiodination, and showed favorable tumor/blood ratios. The selected phage particles (phage 3 or phage 5) were more concentrated in NPC tumors than the control phage (initial phage display peptide library). EY13 could also inhibit the binding of selected phage particles to tumors. The results indicated that EDIKPKTSLAFR was a good candidate in diagnostic and therapeutic NPC.
Developing new drugs that target tumor cell or tumorassociated vasculature is crucial for the improvement of tumor diagnosis and therapy, especially in the early stage [1, 2] . Phage display technology provides a powerful approach for the discovery of new tumor-specific molecules that could create noninvasive molecular imaging. Many peptides identified using phage display technology have shown clinical promise as cancer targeting agents due to higher specific tumor uptake, more rapid tumor penetration and less immunogenicity than monoclonal antibodies [3−6] . Some therapeutic drug-linked peptides selectively homing tumors after intravenous injection showed more marked therapeutic efficiency and less sideeffects than the untargeted drugs [7, 8] .
Many researchers have devoted themselves to the study of the causes inducing tumor formation. Although etiological factors were still not completely identified, one report [9] indicated that various genetic and epigenetic changes in carcinogenic cells and other tumor-associated tissues can result in changes in protein status, including tumor cell receptors and vascular receptors. The complete pictures of these receptors are not well known at present [10] . The application of in vivo phage display technology has an important advantage in that one can select ligands in the environment of the whole animal. This technology might also help us to map the landscape of receptors [11] . It was used by Pasqualini and Ruoslahti to select peptide ligands homing to normal organs, brain and kidneys [12] . The cyclic RGD, a small excellent angiogenic vasculaturetargeting peptide was obtained in this way [7] by the same research group. The rescued phage particles binding selectively to a specified normal tissue, a tumor or other angiogenesisrelated receptors can be titered, amplified and sequenced [13−20] . Different peptide ligands have been selected from http://www.abbs.info; www.blackwellpublishing.com/abbs lung, skin, pancreas, intestine, uterus, retina, adrenal gland and tumor xenografts, as well as brain and kidney, using phage display technology [21−23] . However, many isolated peptides did not show high specificity or affinity to tumors or specific organs. Therefore, Landon et al. pioneered an in vivo selection scheme using a pre-cleared phage library [24, 25] , and some researchers prolonged circulative time in vivo so as to effectively yield phages that display uncommon peptides [19, 20, 24] .
In this article, we selected 1 h as the circulation time of phage, in accordance with relevant reports [19, 20, 24] , and identified a novel dodecapeptide EDIKPKTSLAFR specifically binding to nasopharyngeal carcinoma (NPC) using in vivo phage display. The 13 mer peptides and their derivatives YR13, EY13, EY13NH 2 and Fmoc-YR13 were synthesized and radiolabeled with 131 I, and the in vitro stability and biodistribution was determined. The plasma metabolites of four compounds were analyzed by HPLC. The tissue distribution of phage particles in mice bearing NPC tumor was detected. In addition, we also investigated whether modification of tyrosine modified with Fmoc or NH 2 impaired the affinity.
Materials and Methods

Reagents and equipment
All reagents were of analytical grade and were used without further purification. All water used was deionized. The Ph.D-12 phage display peptide library kit was purchased from NEB (New England Biolabs, Beijing, China). All other reagents were from Beijing Xin Jing Ke Biotechnology (Beijing, China). Polyethylene glycol/NaCl and LB medium (10 g bacto-tryptone, 5 g yeast extract and 5 g NaCl in 1 liter of distilled water) were prepared according to procedures recommended in the NEB product manual. No-carrier-added Na 131 I (aqueous solution) was obtained from the China Institute of Atomic Energy (Beijing, China). DNA was sequenced by Sheng Gong Biotechnology (Shanghai, China). The peptides and their derivatives, YEDIKPKTSLAFR (YR13), EDIKPKTSLAFRY (EY13), EDIKPKTSLAFRY-NH 2 (EY13-NH 2 ) and Fmoc-YEDIKPKTSLAFR (Fmoc-YR13), were synthesized by GL Biochem (Shanghai, China). DMEM-P1 is a mixture containing the protease inhibitor (phenylmethylsulphonyl fluoride) (1 mM), aprotinin (20 µg/ml) and leupeptin (1 µg/ml) in Dulbecco's modified Eagle's medium [11] . Kunming mice (20−22 g, male) were purchased from the Breeding Center of Zoology at Peking University's Health Science Center (Beijing, China). Male nude mice (BALB/c nu) bearing CNE-1 human NPC tumor were supplied by the Breeding Center of Zoology from the Chinese Academy of Medical Science (Beijing, China).
C 18 Sep-Pak cartridges were supplied by Waters Corporation (Milford, USA). A Symmetry C 18 column (5 µm, 3.9×150 mm; Waters) was used to analyze samples [26] . Analytical reverse phase (RP)-HPLC was carried out with the 600E solvent distribution system (Waters). A Packard 500 TR Series Flow Scintillation Analyzer (Ramsey, USA) was used to analyze the radioactivity of tissue samples. The radiochemical yield of labeled compounds was analyzed by a CRC-15R dose-calibrator (Capintec, Ramsey, USA). The matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) mass spectra were provided by the Beijing Mass Spectrometry Center, Chinese Academy of Sciences (Beijing, China).
Phage selection
Athymic nude mice at 4−6 weeks of age were injected subcutaneously in the right flank with CNE-1 human NPC cells (10 7 cells in 200 µl Dulbecco's modified Eagle's medium) [20, 27] . When the tumors reached approximately 0.5−1.0 cm in diameter (20−25 d), the mice bearing NPC tumor were used to carry out biopanning and biodistribution. Biopanning procedures were carried out according to the NEB product manual and the methods reported [7, 12, 20] , with some modifications. Aliquots [200 µl, 10 12 plaque forming unit (PFU)/ml] of phage display peptide library diluted 1:10 in LB medium were injected into the tail vein of mice bearing NPC tumor. After the phage particles circulated for 1 h [19] , the mice were killed by cervical dislocation and tumors were quickly removed and put to DMEM-P1 solution. The phage particles bound to NPC tumors were recovered by adding 1 ml of Escherichia coli 2738 bacterial culture and incubation at room temperature for 30 min [20, 27] . The recovered phages were titered, amplified and purified [19, 28] . The amplified and purified phage particles (10 12 PFU/ml) were again injected into mice as described above. For DNA sequence analysis, individual blue phag plaques were picked out from titer plates grown overnight after the third or fifth round of panning.
Tissue distribution of selected phage particles in organs and tumor xenografts
Mice bearing NPC tumor (three mice for each group) received a separate injection into the tail vein of 10 9 PFU of the third round selected phage and the fifth round selected phage, the fifth round selected phage plus 200 µg EY13 or YP13 [7, 21, 22] (a nonspecific random 13 peptide YSVSVGMLPSHAP as control peptide) and the control phage (initial phage display peptide library). Eight minutes after injection [20] , the mice were killed by cervical dislocation. The tumor nodules and organs such as heart and brain were removed, washed and weighed prior to titering.
In this report, abbreviations have been given to the different kinds of phages to simplify their description: the initial phage display peptide library is phage 1; the phage after the third round selection is phage 3; and the fifth round selected phage is phage 5.
Iodination and radioiodination of peptides and their derivatives
The peptides and their derivatives were labeled with 131 I using the Iodogen method [26] . YR13, EY13, Fmoc-YR13 and EY13NH 2 (30 µg) were added separately to a 0.5 ml polypropylene vial coated with 100 µg Iodogen. Phosphatebuffered saline (PBS; 50 µl, 0.1 M, pH 7.4) and Na ). The radiochemical yield of the labeled products was determined by RP-HPLC on a Waters Symmetry C 18 column (5 µm, 3.9×150 mm) at a flow rate of 1 ml/min, linear gradient from 90% solvent A (water with 0.1% trifluoroacetic acid) and 10% solvent B (acetonitrile with 0.1% trifluoroacetic acid) to 35% solvent A and 65% solvent B in 0−25 min. The labeled mixtures of peptides and derivatives were purified by C 18 SepPak column or RP-HPLC. The radioiodinated products were diluted with PBS to obtain solutions with a radioactivity concentration of 1850 kBq/ml for use in animal experiments.
Octanol/water partition co-efficient
Approximately 10 kBq labeled peptide or derivative in 400 µl PBS was added to 400 µl n-octanol in a centrifugal tube [26] . The two-phase mixtures were vortexed at room temperature for 3 min and centrifuged at 4320 g for 15 min to separate the two phases. PBS and n-octanol (100 µl each) were separately pipeted for radioactivity counting in an automated gamma counter. The partition co-efficient was calculated from three parallel runs.
Stability of [ 131 I] peptides and their derivatives
RP-HPLC was used to evaluate the stability of labeled YR13, EY13NH 2 , EY13 and Fmoc-YR13 in PBS, separately [26, 29] . To 200 µl of PBS was added 100 µl (20−30 µCi) of one of the labeled solutions. The mixtures were incubated at room temperature or 37 ºC. At the incubation time points of 1 h and 24 h, the incubated solutions were analyzed by RP-HPLC with the method described above.
Biodistribution of radiolabeled peptides and their derivatives
Mice bearing NPC tumor were randomly allocated into groups, five mice bearing NPC tumor for each group. Labeled YR13, EY13, EY13NH 2 or Fmoc-YR13 (100 µl, 185 kBq) was injected into the tail vein of each mouse without anesthesia [26, 29] . Mice were killed by cervical dislocation at 30 min, 1 h and 2 h post-injection. The organs or tissues were removed, washed and weighed prior to radioactivity counting. Injection solution (100 µl) was taken as a standard for calculating the percent of injected dose per gram of tissue, that is, %ID/g. The tumor to organ (tissue) ratio for each mouse was also calculated. The final results were expressed as the mean±SD.
In order to investigate what components resulted in the radioactivity in stomach contents, the washing fluid from the stomachs of mice at the 1 h time point was collected and washing mixtures were centrifuged to collect supernatants. The supernatants were passed though a 0.22 µm micropore filter membrane and analyzed by RP-HPLC.
Metabolism
Labeled YR13, EY13, EY13NH 2 or Fmoc-YR13 (100 µl, 7−10 MBq/20 µg) was injected for each normal mouse through the tail vein. Aliquots of blood samples taken at 10 min and 60 min after injection were centrifuged to collect serum (three mice at each time point). Serum was deproteinized by protein precipitation with acetonitrile [29] . The samples were then centrifuged at 4320 g for 15 min. Aliquots of plasma, serum and supernatant after acetonitrile precipitation were counted. The supernatants were concentrated and analyzed by RP-HPLC with the method already described. were picked out for sequencing after three rounds, from which five different sequences were identified, as shown in Table 1 . Of the 10 picked blue plaques, six had the same sequence EDIKPKTSLAFR, but the other four clones had no consistent residues. All 10 sequenced clones had the consistent residue EDIKPKTSLAFR after the fifth round. The N-terminal or C-terminal derivatized peptides with a tyrosine YR13 or EY13, and their derivatives Fmoc-YR13 and EY13NH 2 , were subsequently synthesized. (Fig. 1, up) . The study showed that phage particles homing to NPC tumor could be accumulated after 3−5 rounds of panning in vivo, and the cognate peptide and selected phages possess the same binding site.
Results
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The RP-HPLC analysis results showed that the radiochemical purity of labeled peptides and their derivatives was higher than 90%. The retention times of 131 
Selected phages bind to NPC tumors
The biodistribution of selected phages (phage 3 and phage 5) and the control phage (initial phage library) was investigated in mice bearing NPC tumor. The phage particles were rescued from tumor, brain and heart after phages were injected into mice and circulated for 8 min. The selected phages showed more appreciable enrichment in tumor than control phage, and less phage particles were recovered from control organs (heart and brain). The recovery of phage 5 and phage 3 in tumor was approximately 102-fold and 63-fold higher than that of the control phage, respectively (Fig. 1, down) . This is consistent with the percentage of peptide EDIKPKTSLAFR in phage solutions deduced from the DNA sequences ( Table 1) . The recovery of phage 5 and phage 3 in tumor was approximately 10-fold and 5-fold higher than that in heart, respectively. The selected phages and the control phage did not show any specific targeting to heart tissues ( Fig.  1, up) . Only less phage particles were recovered in brain of mice injected with selected phages and the control phage.
In order to determine whether the synthetic peptide and the selected phage clone competed for the same binding site, the peptide EY13 competitive inhibition assay was carried out (Fig. 1) The activity in serum remained constant at 65%−75% of the one in plasma for labeled YR13, EY13, EY13NH 2 and Fmoc-YR13 after centrifugation. The amount of radioactivity in supernatant of serum deproteinized with acetonotrile was 75%−85% of the activity in serum for the four labeled compounds. Metabolites analysis showed that approximately 80% of the tracer remaining in the serum collected at 10 min post-injection was intact YR13 or EY13; intact Fmoc-YR13 or EY13NH 2 was more than 90% of the tracer in supernatant. Much radioiodine was lost from ]iodo-EY13 at 1 h after injection and only approximately 30% of the activity was contributed by intact peptides (Fig. 2) The accumulation of the radioiodine from labeled Fmoc-YR13 and EY13NH 2 in thyroid of mice bearing NPC tumor was far less than that of labeled YR13 and EY13 (Fig. 3) at the same time points. At 30 min, activity in thyroid of mice was approximately 9.6-fold (YR13/ Fmoc-YR13) and 9.2-fold (EY13/EY13NH 2 ). This result showed that, if blocked, the N-and C-termini of peptides http://www.abbs.info; www.blackwellpublishing.com/abbs are able to inhibit in vivo deiodination. The radioactivity in thyroid of mice injected with EY13 increased more rapidly than with YR13, indicating that radioiodine seems to be easily released by metabolic degradation when tyrosine is added to the C-terminus.
Biodistribution
The biodistribution of labeled EY13NH 2 , YR13, EY13 and Fmoc-YR13 was determined ( Table 2 ). The highest uptake of EY13NH 2 , EY13 and YR13 in NPC tumors appeared at 30 min post-injection (3.72 %ID/g, 3.16 %ID/g and 3.81 %ID/g respectively), and the uptake of Fmoc-YR13 also reached its maximum 1.66 %ID/g at the same time point. It can also be seen that the uptake (%ID/g) of these four compounds in normal tissues was low, their clearance was fast (stomach and intestine excluded) within 2 h and the tumor-to-tissue ratios steadily went up with time ( Table 3) . In blood, the concentration of radioactivity became low at 1 h and 2 h. The tumor/blood ratios of EY13NH 2 , EY13 and YR13 increased continuously: from 0.57 at 30 min to 1.19 of EY13NH 2 at 2 h; from 0.54 at 30 min to 0.93 of EY13 at 2 h; and from 0.51 at 30 min to 1.00 of YR13 at 2 h. Although the uptake of Fmoc-YR13 in most organs (tissues) was similar to the other three compounds, the radioactivity of Fmoc-YR13 in tumor was much lower than that of YR13 so that tumor-to-blood ratios barely increased from 30 min to 120 min.
There (Fig. 4) Perhaps due to different metabolic and excretion modes, the radiotracer of [
131 I]iodo-Fmoc-YR13 in small intestine remained largely and continually increased from 30 min to 2 h, followed by temporary suspension in large intestine. Radioiodide should not be the main chemical form in intestine [26] ; if it is, Na +/ I − symporter (NIS) system could reabsorb it back into the circulatory system, resulting in Table 3 Tumor-to-organ (tissue) ratios of peptides in mice bearing nasopharyngeal carcinoma tumor low radioactivity in intestine [30] . Therefore, in the case of [ 131 I]iodo-Fmoc-YR13, a large part of the radioactivity in intestine could not be radioiodide.
The uptake in stomach of mice injected with labeled YR13, EY13, EY13NH 2 and Fmoc-YR13 showed significant difference. It is possible that YR13, EY13 and EY13NH 2 , whose N-terminals are nude NH 3 are absorbed into stomach by higher acidity. They then go into small intestine and large intestine. Fmoc might hinder Fmoc-YR13 from going into stomach because the N-terminal of YR13 has been blocked. Therefore, the N-terminal state (blocked or not blocked) of peptides and their derivatives might result in their different biodistribution in stomach.
Discussion
Since phage display technology was reported 20 years ago by Smith [31] , a central goal in the field of molecular targeting has been to find new cancer targeting peptides. One novel peptide EDIKPKTSLAFR that targets NPC tumor was identified by in vivo phage display. Lee et al. [20] isolated a 12 mer peptide RLLDTNRPLLPY (Lpeptide) specifically binding to the NPC tumor cell in vitro with a phage display random peptide library. The L-peptide bound to the tumor cell surface of most NPC cell lines and biopsy specimens, but not normal nasal mucosal cells. L-peptide-linked liposomes carrying doxorubicin (Lpeptide-Lipo-Dox) caused marked cytotoxicity in NPC cells and suppressed tumor growth better than Lipo-Dox. Because the biodistribution of L-peptide was not reported in the article and tumor-to-blood ratios were not obtained, it could not be concluded whether L-peptide could be used as an imaging agent. Other studies [6, 24] found that peptides selected in vitro or in situ might not effectively target tumors. Therefore, new targeting peptides should be selected in vivo.
As the original dodecapeptide EDIKPKTSLAFR does not contain suitable structures for labeling, the N-terminal or C-terminal derivatized peptides with a tyrosine YR13 and EY13, and their derivatives Fmoc-YR13 and EY13NH 2 , were synthesized. Labeled YR13, EY13 and EY13NH 2 possessed higher specific uptake and slower clearance rate in tumors. The results indicated that peptide EDIKPKTSLAFR has shown clinical promise as a cancer targeting agent.
Deiodination in vivo of directly radioiodinated peptide has been reported as an important phenomenon [32, 33] . Alternative procedures have been studied to protect peptides from in vivo deiodination. The use of an acylation agent derived from the prototypical N-succinimidyl 3-iodobenzoate for labeling proteins can decrease deiodination in mice [34−36] . Our laboratory found that a radioiodinated N-terminal tyrosine of a peptide that was protected with a t-butyloxycarbonyl group was quite resistant to in vivo deiodination and resulted in rapidly reducing radioactive background and negligible radioactivity accumulation in both thyroid and stomach [26] . In order to improve the quality of peptides and raise stability in vivo, Fmoc, another widely used α-amino-protecting group, was conjugated to YR13, and EY13 was amidated. The uptake of radioiodinated Fmoc-YR13 and EY13NH 2 in thyroid was far lower than that of radioiodinated YR13 and EY13 (Fig.  3) . The RP-HPLC analysis of the serum collected 10 min and 60 min after injection showed that only a little radioiodine was lost from labeled Fmoc-YR13 and EY13NH 2 (Fig. 2) . However, although Fmoc and NH 2 groups have the potency to protect peptides from deiodination, the larger Fmoc group might inhibit peptides from binding to NPC tumor with lower affinity. The amidation of peptide EY13 could not only block deiodination but also obtain a favorable tumor/blood ratio. It might be that the smaller NH 2 − group increases the stability in vivo and does not affect affinity.
The low n-octanol/PBS partition coefficient (Po-w) is often associated with the lower and shorter retention in background tissues and blood [37] . Therefore, the hydropophilic nature of peptides and their derivatives might result in lower uptake of these four compounds in the normal tissues and faster clearance so as to obtain favorable tumor-to-organ (tissue) ratios, except Fmoc-YR13. The synthetic peptide and the selected phage clone competed for the same binding site and illustrated the specificity of the tracer accumulation.
